{"entity":{"id":"nct06393374","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","aka":[],"tldr":"A phase 3 trial of Pembrolizumab, Sacituzumab tirumotecan and Capecitabine in triple-negative breast cancer, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012). ClinicalTrials.gov record last updated 2026-10-06: recruiting. Enrollment is planned at 1530 participants. Primary completion is estimated at 2030-12-16. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Pembrolizumab, Sacituzumab tirumotecan, Capecitabine. Registered primary measures: Invasive Disease-Free Survival (iDFS).","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06393374","url":"https://clinicaltrials.gov/study/NCT06393374"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc","tnbc-early"],"sections":[],"technologies":["adc","checkpoint-inhibitor","topoisomerase-inhibitors"],"targets":["trop2"],"drugs":["pembrolizumab","sacituzumab-tirumotecan","capecitabine"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-10-06: recruiting. Enrollment is planned at 1530 participants. Primary completion is estimated at 2030-12-16. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT06393374","phase":"3","setting":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","sponsor":"Merck Sharp & Dohme LLC","participation":[{"nct":"NCT06393374","source":"https://clinicaltrials.gov/study/NCT06393374","fetchedAt":"2026-10-07T16:54:38.047Z","studySha256":"4eb922afe70f1ebb9880f82ace700bdb1f3754c50496247e3aa9c9e8a38c7585","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-06","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":1530,"enrolmentType":"ESTIMATED","siteCount":314,"recruitingSiteCount":300,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Canada","Colombia","Czechia","Denmark","Finland","France","Germany","Greece","Hong Kong","Ireland","Israel","Italy","Japan","Malaysia","Mexico","Norway","Poland","Portugal","Singapore","South Korea","Spain","Sweden","Switzerland","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2024-06-24","startedType":"actual","enrolled":1530,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06393374/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}